Once-Daily Dosing Regimen for Aminoglycoside plus Betalactam Combination Therapy of Serious Lower Respiratory Tract Infections

REFERENCES

• Paradisi F. Terapia delle infezioni. 2nd ed. Torino: UTET, 1993: 78–84.
   Google Scholar
• Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th ed. New York: Churchill Livingstone, 1995: 279–306.
   Google Scholar
• Dombusch K, Miller GH, Hare RS, Shaw KJ and the ESGAR Study Group. Resistance to aminoglycoside antibi-otics in Gram-negative bacilli and staphylococci isolated from blood. Report from a European collaborative study. J Antimicrob Chemother 1990; 26: 131–44.
   Google Scholar
• John JF. What price success? The continuing saga of the toxic:therapeutic ratio in the use of aminoglycoside antibi-otics. J Infect Dis 1988; 158: 1–6.
   PubMed Web of Science ®Google Scholar
• Kaye D, Levison ME, Labovitz ED. Unpredictability of serum concentrations of gentamicin: pharmacokinetics of gen-tamicin in patients with normal and abnormal renal function. J Infect Dis 1974; 130: 150–4.
   PubMed Web of Science ®Google Scholar
• Nordstrom L, Ringberg H, Cronberg S, Tjemstrom O, Walder M. Does the administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990; 25: 159–73.
   PubMed Web of Science ®Google Scholar
• Nordstrom L, Banck G, Belfrage S, Juhlin I, Tjemstrom O, Toremalm NG. Prospective study of the ototoxicity of gentamicin. Acta Pathol Microbiol Scand, Section B 1973; 81 (suppl 241): 58-61.
   Google Scholar
• Noone P, Parsons TMC, Pattison JR, Slack RCB, Garfield-Davies D, Hughes K. Experience in monitoring gen-tamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974; i: 477–81.
   Google Scholar
• Labovitz E, Levison ME, Kaye D. Single-dose daily gen-tamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974; 6: 465–70.
   PubMed Web of Science ®Google Scholar
• Parker SE, Davey PG. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1993; 31: 4–8.
   PubMed Web of Science ®Google Scholar
• Jangknet R. Aminoglycoside monitoring in the once- or twice-daily era. The Dutch situation considered. Pharm World Sci 1993; 15: 151–5.
   PubMedGoogle Scholar
• Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399–405.
   PubMed Web of Science ®Google Scholar
• Perea EJ. El tratamiento con aminogluaisidos en dosis Unica diaria. Rev Esp Quimioterap 1994; 7: 183–6.
   Google Scholar
• Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100: 352–7.
   PubMed Web of Science ®Google Scholar
• Tally FP, Louie TJ, Weinstein WM, Bartlett JG, Gorbach SL. Amikacin therapy for severe gram-negative sep-sis: emphasis on infections with gentamicin-resistant organ-isms. Ann Intern Med 1975; 83: 484–8.
   PubMed Web of Science ®Google Scholar
• Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149: 443–8.
   PubMed Web of Science ®Google Scholar
• Pechere J-C, Craig WA, Meunier F. Once daily dosing of aminoglycoside: one step forward. J Antimicrob Chemother 1991; 27 (suppl C): 149-52.
   Google Scholar
• Kumana CR, Yuen KY. Parenteral aminoglycoside ther-apy. Selection, administration and monitoring. Drugs 1994; 47: 902–13.
   Google Scholar
• Gladen HE, Jackson JD, Jordan JT. Antibiotics, DRGs, and the personal computer: simple techniques to estimate true cost. Infections in Surgery, SCP Communications Inc. 1986; 5: 559–64.
   Google Scholar
• Eisenberg JM, Koffer H, Glick HA. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900–9.
   PubMed Web of Science ®Google Scholar
• Maller R, Isaksson B, Nilsson L, Soren L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother 1988; 22: 75–9.
   PubMed Web of Science ®Google Scholar
• Mailer R, Ahme H, Eilard T, Eriksson I, Lausen I and the Scandinavian Amikacin Once Daily Study Group. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J Antimicrob Chemother 1991; 27 (suppl C): 121-8.
   Google Scholar
• Maller R, Ahrne H, Holmen C, et al. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic Gram-negative infections. J Antimicrob Chemother 1993; 31: 939–48.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Yiallouros K, Petrikkos G, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic Gram-nega-tive infections. J Antimicrob Chemother 1991; 27 (suppl C): 73-9.
   Google Scholar
• Prins JM, Boller ITR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with seri-ous infections. Lancet 1993; i: 335–9.
   Google Scholar
• De Vries PJ, Leguit P, Verkooyen RP, Verbrugh HA. Toxicity of once daily netilmicin in patients with intraabdominal infections. Proceedings of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. New York: American Society for Microbiology, 1987: 203.
   Google Scholar
• Fan ST, Lau WY, Teoh-Chan CH, Lau KF, Mauracher EH. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gan-grenous and perforated appendicitis. J Antimicrob Chemother 1988; 22: 69–74.
   PubMed Web of Science ®Google Scholar
• Tulkens PM, Clerckx-Braun F, Dounez J, et al. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev 1988; 1 (suppl 3): 71-82.
   Google Scholar
• HoRender LF, Bahnini J, De Manzini N, et al. A multi-centric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infec-tions. J Antimicrob Chemother 1989; 23: 773–83.
   PubMed Web of Science ®Google Scholar
• Sturm AW. Netilmicin in the treatment of gram-nega-tive bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989; 159: 931–7.
   PubMed Web of Science ®Google Scholar
• Ter Braak EW, de Vries PJ, Bouter KIP, et al. Once-daily dosing regimen for aminoglycoside plus B-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58–66.
   PubMed Web of Science ®Google Scholar
• Heininger U, Bowing B, Stehr K, Solbach W. Aminoglykoside bei patienten mit mukoviszidose und pul-monaler exazerbation: vergleich von einmal- und dreimal-gabe. Kiln Padiatr 1993; 205: 18–22.
   PubMed Web of Science ®Google Scholar
• Raz R, Adawi M, Romano S. Intravenous administra-tion of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis 1995; 14: 88–91.
   PubMed Web of Science ®Google Scholar
• Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302: 1106–9.
   PubMed Web of Science ®Google Scholar
• The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC). Efficacy and toxicity of sin-gle daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–93.
   Google Scholar
• Tulkens PM. Pharmacokinetic and toxicological evalua-tion of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991; 27 (suppl C): 49-61.
   Google Scholar
• Ibrahim S, Derde MP, Kaufman L, et al. Safety, phar-macokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suf-fering from pelvic inflammatory disease. Ren Fail 1990; 12: 199–203.
   PubMed Web of Science ®Google Scholar
• Mattie H, Craig WA, Pechere JC. Determinants of effi-cacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989; 24: 281–93.
   PubMed Web of Science ®Google Scholar
• Meunier F, Van der Auwera P, Aoun M, Ibrahim S, Tulkens PM. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocy-topenic patients: a pilot study. J Antimicrob Chemother 1991; 27 (suppl C): 129-39.
   Google Scholar
• Suwangool P, Aswapokee N, Sathapatayavongs B, et al. Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone. J Med Assoc Thai 1993; 76: 314–8.
   PubMedGoogle Scholar
• Gibson J, Johnson L, Snowdon L, et al. A randomised dosage study of ceftazidime with single daily tobramycin for the empirical management of febrile neutropenia in patients with hematological diseases. Int J Hematol 1994; 60: 119–27.
   PubMed Web of Science ®Google Scholar
• Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with B-lactam antibiotics as empirical therapy for febrile neu-tropenic patients. J Antimicrob Chemother 1993; 31: 585–98.
   PubMed Web of Science ®Google Scholar
• Fraschini F, Braga PC, Scarpazza G, et al. Human pharmacokinetics and distribution in various tissues of ceftri-axone. Chemotherapy 1986; 32: 192–9.
   PubMed Web of Science ®Google Scholar
• Pennington JE. Penetration of antibiotics into respira-tory secretions. Rev Infect Dis 1981; 3: 67–73.
   PubMedGoogle Scholar
• Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77: 657–62.
   PubMed Web of Science ®Google Scholar
• Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988; 158: 7–12.
   PubMed Web of Science ®Google Scholar
• Periti P, Novelli A, Grassi C, Meli E, Melani A, Mazzei T. Once-daily compared with twice-daily administration of netilmicin in the treatment of respiratory tract infectious dis-ease. J Chemother 1991; 3 (suppl 4): 323-5.
   Google Scholar
• Pegram PS, Phair JP, McMahan R, et al. Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. J Antimicrob Chemother 1989; 24: 591–604.
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Hathom JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–8.
   PubMed Web of Science ®Google Scholar
• Davis PB, Di Sant'Agnese PA. A review. Cystic fibrosis at forty - quo vadis? Pediatr Res 1980; 14: 83–7.
   Google Scholar
• Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988; 35: 542–78.
   PubMed Web of Science ®Google Scholar
• Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Tobramycin: a review of its antibacterial and phar-macokinetic properties and therapeutic use. Drugs 1976; 12: 166–200.
   PubMed Web of Science ®Google Scholar
• Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxi-city in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983; 147: 918–32.
   Google Scholar
• McCrae WM, Raeburn JA, Hanson EJ. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentra-tion of antibiotic in sputum. J Infect Dis 1976; 134: 1915–8.
   Google Scholar